RCS - BB Biotech AG - Edison issues review on BB Biotech (BION)
14/09/2022 08:45
For best results when printing this announcement, please click on link below: http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220914:nRSN3248Za&default-theme=true RNS Number : 3248Z BB Biotech AG 14 September 2022 London, UK, 14 September 2022 Edison issues review on BB Biotech (BION) According to BB Biotech's (BION) investment team, the biotech industry has never looked in such a good position. Following a sell-off in the last 18 months, a combination of fundamental industry strength and discounted valuations has recently attracted investors to return to the biotech market. In the sector, BION is differentiated from the Nasdaq Biotechnology Index by its concentrated portfolio (c 30 stocks) of what the investment manager, Bellevue Asset Management, believes to be best-in-class biotech growth opportunities. The BION team continues to focus on its core portfolio of biotech staples, such as Moderna, blended with undiscovered, innovative companies, bringing new technologies. BION's current 3.9% premium to NAV is below its historical averages of 25.2% and 13.5% (over one and five years, respectively). BION paid a dividend of CHF3.85 per share) for FY21, equal to a 5% yield at an average FY21 share price. Click here (https://www.edisongroup.com/publication/great-valuation-potential/31333/?utm_campaign=RNSreach%20Press%20Releases&utm_source=RNSreach&utm_medium=Press%20Release) to view the full report or here (https://share.hsforms.com/14ENcGBFTQfmT6UkoLH7ZgA3k1vq) to sign up to receive research as it is published. All reports published by Edison are available to download free of charge from its website www.edisongroup.com (http://www.edisongroup.com) About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings. Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney. Edison is authorised and regulated by the Financial Conduct Authority (https://register.fca.org.uk/ShPo_FirmDetailsPage?id=001b000000MfYL6AAN) . Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities. For more information, please contact Edison: Victoria Chernykh +44 (0)20 3077 5700 investmenttrusts@edisongroup.com (mailto:investmenttrusts@edisongroup.com) Learn more at www.edisongroup.com (http://www.edisongroup.com) and connect with Edison on: LinkedIn www.linkedin.com/company/edison-group-/ (http://www.linkedin.com/company/edison-group-/) Twitter www.twitter.com/Edison_Inv_Res (http://www.twitter.com/Edison_Inv_Res) YouTube www.youtube.com/edisonitv (http://www.youtube.com/edisonitv) This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com (mailto:rns@lseg.com) or visit www.rns.com (http://www.rns.com/) . Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy) . END NRAFLFLEAIIVLIF